Clinical study on drug interactions and dosage administration of therapeutic drugs for nontuberculous mycobacterium infection. - Clinical study on drug interactions and dosage administration of therapeutic drugs for nontuberculous mycobacterium infection.

aboratory of pharmacotherapeutics, Tokyo University of Science0 个研究点目标入组 25 人开始时间: 2012年11月15日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 25

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Our study demonstrated consistently low levels of serum CAM due to RFP-mediated induction of CYP3A4 in pulmonary MAC disease patients treated with a standard combination of CAM and RFP. These continuously low concentrations of CAM are suggested to be responsible for unsatisfactory clinical outcomes of this disease.

研究设计

研究类型: Observational

入排标准

年龄范围: 20years-old 至 80years-old（—）
性别: All

入选标准

未提供

排除标准

•1)Subjects whose PS(Performance Status)are over 7 accordance with the Ordinance of the Ministry of Health, Labour and Welfare. 2)Subjects who had in the past or currently have following diseases. ;hepatic or renal diseases ;other diseases which doctor in attendance considered to influence in results of study, or be penalized by administration of clarithromycin, rifampicin and ethambutol. 3)Subjects who consumed excessive amounts of coffee or beverage containing caffeine.(over eight cups a day) 4)Drug or alcohol abuser. 5)Illegal drug constant user. 6)Men and women who donated two hundred milliliter of blood within four weeks prior to commencement of this study, or men who donated four hundred milliliter of blood within twelve weeks prior to commencement of this study, and women who donated four hundred milliliter of blood within sixteen weeks prior to commencement of this study. 7)Subjects who participated in another clinical trials with an investigational agent within four weeks prior to commencement of this study. 8)Subjects who had history of hypersensitivity to constituent of RIFADIN CAPSULES, CLARITH TABLETS and ESANBUTOL TABLETS. 9)Subjects who are judged as inadequate by doctor in attendance.

研究者

发起方

aboratory of pharmacotherapeutics, Tokyo University of Science

相似试验

已完成

1 期

Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy VolunteersPharmacokinetics

NCT01124760AstraZeneca28

已完成

1 期

Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy VolunteersHealthy

NCT03760848Galmed Pharmaceuticals Ltd15

已完成

1 期

Effect of Itraconazole on the Pharmacokinetics of BIIB074Neuropathic Pain

NCT02698267Biogen16

已完成

1 期

Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib PharmacokineticsHealthy Volunteers

NCT02430545Pfizer12

已完成

1 期

A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult ParticipantsHealthy Volunteers

NCT05994807DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company33